

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/529,071
	Filing Date:	March 24, 2005
	First Named Inventor:	Li et al.
	Group:	Not assigned
	Examiner:	Not assigned
Attorney Docket No.:		180/156 PCT/US

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
/SL/	1	US 2001/0053352	12/20/2001	Yu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
/SL/	2	WO 98/35028	8/13/1998	Aleman et al.		
/SL/	3	WO 02/26192	4/42002	Van Meir et al.		

OTHER DOCUMENTS


Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
/SL/	4	International Search Report corresponding to PCT App. No. PCT/US03/31097 dated April 21, 2004.	
/SL/	5	HUANG ET AL., "A Hypoxia-Selective Oncolytic Adenovirus for Cancer Therapy", <u>I. J. Radiation Oncology</u> , 54(2) Supplement : 122, 2002.	
/SL/	6	LIU ET AL., "Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells", <u>Circulation Research</u> , 77(3) : 638, September 1995.	
/SL/	7	SHIBATA ET AL., "Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes", <u>I.J. Radiation Oncology Biol. Phys.</u> , 42(4) : 913-916, 1998.	



/SL/	8	BOSHART ET AL., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus", <u>Cell</u> , 41: 521-530, June 1995.	
/SL/	9	HERNANDEZ-ALCOCEBA ET AL., "New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication", <u>Human Gene Therapy</u> , 13: 1737-1750, September 20, 2002.	
/SL/	10	POST ET AL., "A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy", <u>Oncogene</u> , 22: 2065-2072, 2003.	
/SL/	11	SHIBATA ET AL., "Development of a hypoxia-responsive vector for tumor-specific gene therapy", <u>Gene Therapy</u> , 7: 493-498, 2000.	

EXAMINER /Scott Long/ DATE CONSIDERED 09/08/2007

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1600 U.S. Department of Commerce
Patent and Trademark Office

List of Documents Cited by Applicant

Application No.:	10/529,071
Filing Date:	March 24, 2005
First Named Inventor:	Li et al.
Group:	1632
Examiner:	Not assigned
Attorney Docket No.:	180/156 PCT/US

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
/SL/	A	Koshikawa et al. <i>Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.</i> <i>Cancer Research</i> , Vol. 60, (2000), pp.2936-2941	
/SL/	B	Griffiths et al. <i>The macrophage – a novel system to deliver gene therapy to pathological hypoxia.</i> <i>Gene Therapy</i> , Vol. 7, (2000), pp.255-262	
/SL/	C	Kurihara et al. <i>Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.</i> <i>The Journal of Clinical Investigation</i> , Vol. 106, no. 6, (2000), pp.763-771	

/SL/	D	Kruyt et al. <i>Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis.</i> <i>Human Gene Therapy</i> , Vol. 13, (2002), pp.485-495	
/SL/	E	Supplementary Partial European Search Report corresponding to EP application No. EP 03799374 dated November 24, 2006.	

EXAMINER /Scott Long/ DATE CONSIDERED 09/08/2007

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**FORM PTO-1449** U.S. Department of Commerce
Patent and Trademark Office

Application No.:	10/529,071
Filing Date:	March 24, 2005
First Named Inventor:	Li et al.
Group:	1632
Examiner:	Not assigned
Attorney Docket No.:	180/156 PCT/US

List of Documents Cited by Applicant

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
/SL/	A	EP Office Action corresponding to an EP Patent Application No. 03799374.8 dated April 19, 2007	
/SL/	B	Indian Office Action corresponding to an IN Patent Application No. 1197//DELNP/2005 dated April 9, 2007	

EXAMINER /Scott Long/ DATE CONSIDERED 09/08/2007

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.